二十碳五烯酸乙酯对接受他汀治疗且甘油三酯升高患者冠状动脉粥样硬化进展的影响:EVAPORATE试验最终结果
EVAPORATE是一项随机双盲安慰剂对照试验,纳入80例接受他汀治疗且甘油三酯持续升高的冠状动脉粥样硬化患者,评估二十碳五烯酸乙酯(IPE)4 g/天对斑块体积的影响。18个月时,IPE组低衰减斑块体积减少17%,而安慰剂组增加109%(P=0.0061),纤维性和纤维脂肪性斑块体积也呈现显著组间差异。
要点
- IPE 4 g/天在他汀治疗基础上可显著减少低衰减斑块体积。
- 安慰剂组低衰减斑块体积增加109%,而IPE组减少17%。
- 纤维性和纤维脂肪性斑块体积在IPE组消退,在安慰剂组进展。
核心结论
- 在他汀治疗且甘油三酯升高的冠状动脉粥样硬化患者中,二十碳五烯酸乙酯(IPE)4 g/天治疗18个月可显著消退低衰减斑块体积。
研究设计与样本
- 随机、双盲、安慰剂对照试验,共纳入80例接受他汀治疗、经多排CT证实冠状动脉粥样硬化(至少一处狭窄≥20%)且甘油三酯持续升高的患者。
- 患者随机接受IPE 4 g/天或安慰剂,并在9个月和18个月时进行冠状动脉CT血管造影扫描。
- 预设主要终点为18个月时IPE组与安慰剂组低衰减斑块(LAP)体积的变化。
主要发现
- IPE组低衰减斑块体积减少17%,安慰剂组增加109%,组间差异显著(P=0.0061)。
- 纤维性和纤维脂肪性斑块体积在IPE组消退、在安慰剂组进展,组间进展率差异显著(P<0.01)。
- 调整年龄、性别、糖尿病状态、高血压和基线甘油三酯后,组间斑块体积变化仍显著不同(P<0.01)。
- 致密钙化斑块在多变量模型中组间差异未达显著(P=0.053)。
- 基线时中位甘油三酯水平为259.1 ± 78.1 mg/dL。
临床怎么用
- 对于接受他汀治疗但甘油三酯仍升高的冠状动脉粥样硬化患者,可考虑加用IPE 4 g/天以延缓斑块进展。
- EVAPORATE试验提供的斑块机制数据可能与REDUCE-IT试验结果及IPE的临床使用相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a statin was shown to reduce initial CV events by 25% and total CV events by 32% in the REDUCE-IT trial, with the mechanisms of benefit not yet fully explained. The EVAPORATE trial sought to determine whether IPE 4 g/day, as an adjunct to diet and statin therapy, would result in a greater change from baseline in plaque volume, measured by serial multidetector computed tomography (MDCT), than placebo in statin-treated patients. METHODS AND RESULTS: A total of 80 patients were enrolled in this randomized, double-blind, placebo-controlled trial. Patients had to have coronary atherosclerosis as documented by MDCT (one or more angiographic stenoses with ≥20% narrowing), be on statin therapy, and have persistently elevated triglyceride (TG) levels. Patients underwent an interim scan at 9 months and a final scan at 18 months with coronary computed tomographic angiography. The pre-specified primary endpoint was change in low-attenuation plaque (LAP) volume at 18 months between IPE and placebo groups. Baseline demographics, vitals, and laboratory results were not significantly different between the IPE and placebo groups; the median TG level was 259.1 ± 78.1 mg/dL. There was a significant reduction in the primary endpoint as IPE reduced LAP plaque volume by 17%, while in the placebo group LAP plaque volume more than doubled (+109%) (P = 0.0061). There were significant differences in rates of progression between IPE and placebo at study end involving other plaque volumes including fibrous, and fibrofatty (FF) plaque volumes which regressed in the IPE group and progressed in the placebo group (P < 0.01 for all). When further adjusted for age, sex, diabetes status, hypertension, and baseline TG, plaque volume changes between groups remained significantly different, P < 0.01. Only dense calcium did not show a significant difference between groups in multivariable modelling (P = 0.053). CONCLUSIONS: Icosapent ethyl demonstrated significant regression of LAP volume on MDCT compared with placebo over 18 months. EVAPORATE provides important mechanistic data on plaque characteristics that may have relevance to the REDUCE-IT results and clinical use of IPE.
引用
- Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020. PMID: 32860032. doi:10.1093/eurheartj/ehaa652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。